BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16888916)

  • 21. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
    Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
    Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
    Lamant L; Gascoyne RD; Duplantier MM; Armstrong F; Raghab A; Chhanabhai M; Rajcan-Separovic E; Raghab J; Delsol G; Espinos E
    Genes Chromosomes Cancer; 2003 Aug; 37(4):427-32. PubMed ID: 12800156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma.
    Trinei M; Lanfrancone L; Campo E; Pulford K; Mason DY; Pelicci PG; Falini B
    Cancer Res; 2000 Feb; 60(4):793-8. PubMed ID: 10706082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of anaplastic lymphoma kinase variant translocations using 5'RACE.
    Hernández L; Campo E
    Methods Mol Med; 2005; 115():295-314. PubMed ID: 15998975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translocations involving anaplastic lymphoma kinase (ALK).
    Duyster J; Bai RY; Morris SW
    Oncogene; 2001 Sep; 20(40):5623-37. PubMed ID: 11607814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma.
    Ladanyi M
    Cancer Surv; 1997; 30():59-75. PubMed ID: 9547986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.
    Chiarle R; Simmons WJ; Cai H; Dhall G; Zamo A; Raz R; Karras JG; Levy DE; Inghirami G
    Nat Med; 2005 Jun; 11(6):623-9. PubMed ID: 15895073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas.
    Bullrich F; Morris SW; Hummel M; Pileri S; Stein H; Croce CM
    Cancer Res; 1994 Jun; 54(11):2873-7. PubMed ID: 8187071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
    Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.
    Maes B; Vanhentenrijk V; Wlodarska I; Cools J; Peeters B; Marynen P; de Wolf-Peeters C
    Am J Pathol; 2001 Jun; 158(6):2185-93. PubMed ID: 11395396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
    Turner SD; Alexander DR
    Leukemia; 2005 Jul; 19(7):1128-34. PubMed ID: 15902287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical screening for oncogenic tyrosine kinase activation.
    Pulford K; Delsol G; Roncador G; Biddolph S; Jones M; Mason DY
    J Pathol; 1999 Apr; 187(5):588-93. PubMed ID: 10398126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
    Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
    Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells.
    Armstrong F; Duplantier MM; Trempat P; Hieblot C; Lamant L; Espinos E; Racaud-Sultan C; Allouche M; Campo E; Delsol G; Touriol C
    Oncogene; 2004 Aug; 23(36):6071-82. PubMed ID: 15208656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
    Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F
    Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K.
    Polgar D; Leisser C; Maier S; Strasser S; Rüger B; Dettke M; Khorchide M; Simonitsch I; Cerni C; Krupitza G
    Mutat Res; 2005 Feb; 570(1):9-15. PubMed ID: 15680399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
    Lamant L; Dastugue N; Pulford K; Delsol G; Mariamé B
    Blood; 1999 May; 93(9):3088-95. PubMed ID: 10216106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
    Kalinova M; Krskova L; Brizova H; Kabickova E; Kepak T; Kodet R
    Leuk Res; 2008 Jan; 32(1):25-32. PubMed ID: 17320171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?
    Fornari A; Piva R; Chiarle R; Novero D; Inghirami G
    Hematol Oncol; 2009 Dec; 27(4):161-70. PubMed ID: 19358142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.